Candy giant Mars partners with biotech firm to gene-edit cocoa supply

Candy giant Mars partners with biotech firm to gene-edit cocoa supply


Packages of M&M’s milk chocolate candy are stacked at a Costco Wholesale store on July 12, 2025 in San Diego, California.

Kevin Carter | Getty Images News | Getty Images

Candy maker Mars said Wednesday it’s partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology.

The agreement gives the M&M’s maker access to Pairwise’s Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable.

CRISPR is a gene editing tool that makes fast and precise changes to DNA. In farming, it’s used to improve crops by targeting different traits like drought and disease resistance.

The goal is to create cacao plants — the source of cacao beans, which are then roasted and made into cocoa — that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.

In October, Starbucks invested in two innovation farms in Central America to protect the chain’s coffee supply from global warming. The farms develop climate-resilient coffee and test technologies like drones and mechanization.

Gene editing allows for faster and more precise trait development than traditional breeding, Pairwise said in a press release.

CRISPR has garnered attention in recent years for its applications in health care. In late 2023, the U.S. Food and Drug Administration approved the first gene-editing treatment for sickle cell disease.

“At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains,” said Carl Jones, Plant Sciences Director at Mars, in the release.

Last month, the candy giant announced a $2 billion investment in U.S. manufacturing through 2026. This includes a new $240 million investment for a Nature’s Bakery facility in Utah.



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More